Home ›
Lymphoma Trials ›
NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Trial Details
NCT ID NCT04998669
Phase PHASE2
Sponsor Juan P. Alderuccio, MD
Status RECRUITING
Cancer Type Lymphoma
Interventions Loncastuximab tesirine Rituximab
Locations (sample) Fort Myers, Florida, United States|26.62168,-81.84059 Miami, Florida, United States|25.77427,-80.19366 Ann Arbor, Michigan, United States|42.27756,-83.74088 New Brunswick, New Jersey, United States|40.48622,-74.45182 Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
Key Eligibility Criteria
Men and women ≥ 18 years of age. Patients must have histologic confirmation of Follicular Lymphoma (FL) (grade 1, 2 and 3A). Note: Participants who have received previous CD19-dire… Patients with relapsed or refractory FL previously treated with ≥1 line of systemic therapy having ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria… Baseline FDG-PET/CT scans must demonstrate positive lesions compatible with CT defined anatomical tumor sites. Patients should have at least one me…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →